Treatment of AML cell lines with rapamycin (29) or decitabine (30) leads to a downregulation of NKG2D ligands, which is associated with an increased activation of STAT3 but no causative relationship was demonstrated. Here, STAT3 is linked to acute myeloid leukemia.